{"filing":{"accession_number":"0001171843-26-005524","cik":"0001771885","ticker":"QNTM","company_name":"Quantum Biopharma Ltd.","form":"6-K","filing_date":"2026-08-14","report_date":"2026-08-14","primary_document":"f6k_081426.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1771885/000117184326005524/f6k_081426.htm"},"events":[{"id":27708,"run_id":25285,"accession_number":"0001171843-26-005524","anchor_item_number":"EX-99.1","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"This is a press release announcing Q2 2026 financial and operational results for Quantum BioPharma, including cash position (US$9.5M), balance sheet metrics, reduced operating expenses (53% decrease YoY), and a material regulatory milestone—FDA approval to proceed with the Lucid-MS Phase 2 clinical trial. The disclosure of quarterly financial results combined with the pivotal clinical development milestone makes this a material earnings release that would affect a reasonable investor's assessment of the company's financial health and pipeline progress.","company_name":"Quantum Biopharma Ltd.","ticker":"QNTM","filing_date":"2026-08-14","form":"6-K","submitted_at":null,"items":[{"id":29355,"accession_number":"0001171843-26-005524","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This is a press release announcing Q2 2026 financial and operational results for Quantum BioPharma, including cash position (US$9.5M), balance sheet metrics, reduced operating expenses (53% decrease YoY), and a material regulatory milestone—FDA approval to proceed with the Lucid-MS Phase 2 clinical trial. The disclosure of quarterly financial results combined with the pivotal clinical development milestone makes this a material earnings release that would affect a reasonable investor's assessment of the company's financial health and pipeline progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-14T11:00:38.144814+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29355,"accession_number":"0001171843-26-005524","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This is a press release announcing Q2 2026 financial and operational results for Quantum BioPharma, including cash position (US$9.5M), balance sheet metrics, reduced operating expenses (53% decrease YoY), and a material regulatory milestone—FDA approval to proceed with the Lucid-MS Phase 2 clinical trial. The disclosure of quarterly financial results combined with the pivotal clinical development milestone makes this a material earnings release that would affect a reasonable investor's assessment of the company's financial health and pipeline progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-14T11:00:38.144814+00:00","company_name":"Quantum Biopharma Ltd.","ticker":"QNTM","filing_date":"2026-08-14"}]}